隶属于 carl-zeiss-stiftung
相关临床试验
57
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2002
已完成
39
68.4%
尚未招募
3
5.3%
招募中
9
15.8%
终止
3
5.3%
Unknown
2
3.5%
撤回
1
1.8%
暂无批准数据
- Zeiss Medical Technology announced FDA 510(k) clearance for Zeiss Clinic 360, an all-in-one cloud and browser-based software solution for ophthalmic workflows. - The platform consolidates diagnostic device data, electronic medical records, and practice systems into a comprehensive patient view to support disease progression evaluation and treatment decisions. - Zeiss Clinic 360 will be available in the U.S. in early fall 2026, offering a subscription-based, scalable alternative to the on-premise Zeiss Forum data management system. - The solution enables clinicians to monitor glaucoma progression using color-coded alerts and trend analysis of OCT, IOP, and visual field data.
- ZEISS Medical Technology reports successful early clinical implantations of the AT LUCIA toric 721P intraocular lens across six European countries, with surgeons describing it as a potential "game changer" for refractive outcomes. - The lens features an aspheric bitoric optic with a patented non-constant aberration design (ZO optic) on a fully preloaded, hydrophobic c-Loop platform, targeting both cataracts and astigmatism simultaneously. - Early surgeon feedback highlights the lens's outstanding rotational stability, precision, ease of implantation, and consistent visual outcomes compared with other toric IOLs. - Currently CE marked, the AT LUCIA toric 721P will be showcased at DOC 2026 in Nuremberg and is expected to reach select European markets later this year.
- ZEISS Medical Technology received China's NMPA approval for the ARTEVO 750 and ARTEVO 850 ophthalmic microscopes, expanding surgical visualization capabilities for Chinese ophthalmologists. - The ARTEVO 750 features enhanced resolution, intelligent RGB illumination, and intraoperative OCT for routine and complex procedures including cataract surgery, vitreoretinal surgery, and MIGS. - The ARTEVO 850 offers 3D digital visualization with up to 60% depth of field optimization and Digital Color Assistant technology for improved anatomical detail visualization. - Chinese ophthalmologists report improved surgical capabilities and reduced fatigue with the new microscope systems, which integrate seamlessly into ZEISS's comprehensive ophthalmic workflows.
- ZEISS Medical Technology announced CE mark approval for CIRRUS PathFinder, an AI-powered clinical support tool that uses deep learning algorithms to automatically identify abnormal macular OCT B-scans. - The fully integrated AI decision support system flags B-scans requiring further review and allows assessment of hundreds of scans in real time without requiring third-party platforms. - The new CIRRUS software release includes AI-enhanced OCTA image quality, multi-layer segmentation, and an expanded Reference Database triple the size of the previous version. - Research indicates that physicians leveraging AI algorithms can be more effective than practitioners working alone, supporting more confident decision-making and efficient patient care.
- ZEISS Medical Technology announced that its CLARUS 700 ultra-widefield fundus imaging camera has received National Medical Products Administration (NMPA) approval in China, expanding access to advanced retinal diagnostic capabilities. - The system integrates ultra-widefield fluorescein angiography with true-color reproduction, capturing 133° in a single image and up to 267° with multiple captures for comprehensive retinal visualization. - The device features AI-enhanced capture technology and innovative tools including PrecisionFocus, QuickCompare, and AutoBright to enhance diagnostic precision and workflow efficiency for Chinese ophthalmologists.
- ILM-Blue, a vital staining dye used in vitreoretinal surgery, has received NMPA approval in China, becoming the first DORC posterior dye product available in the Chinese market. - The product, which has been used in over 900,000 procedures worldwide since 2010, helps surgeons clearly distinguish the inner limiting membrane from underlying retinal layers, reducing risk of retinal damage. - This approval marks a significant milestone for ZEISS Medical Technology and DORC International following their April 2024 acquisition, reinforcing their commitment to expanding innovative ophthalmic solutions globally.
- ZEISS Medical Technology has secured NMPA approval in China for the VISUMAX 800 with SMILE pro software, designed to treat nearsightedness with or without astigmatism. - The advanced femtosecond laser system offers faster treatment times of less than 10 seconds per lenticule creation, utilizing a 2 MHz laser pulse repetition rate. - The system introduces enhanced workflow features including CentraLign centration aid, OcuLign cyclotorsion adjustment, and VISULYZE user nomograms for improved surgical precision and data analysis.
